{"id":"W3161800158","doi":"10.1016/s1470-2045(21)00090-5","title":"Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":327,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Vifor Pharma; European Organisation for Research and Treatment of Cancer; National Cancer Institute; Medac; KWF Kankerbestrijding; Daiichi-Sankyo; Brain Tumour Charity; NRG Oncology; Atara Biotherapeutics; AstraZeneca; American College of Radiology; Novocure; Douglas Pharmaceuticals; Merck Sharp and Dohme; Cancer Australia; National Health and Medical Research Council; Cancer Research UK; Medical Research Council; Celgene","keywords":"Temozolomide; Medicine; Internal medicine; Oncology; Interim analysis; Radiation therapy; Glioma; Dacarbazine; Clinical trial; Chemotherapy; Cancer research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002926899,0.001833634,0.003183167,0.0005259038,0.0004296047,0.001314907,0.0009514464,0.001636994,0.005841802],"category_scores_gemma":[0.001722882,0.000744152,0.002233337,0.0005289015,0.001366936,0.001567413,0.0004859389,0.003552418,0.00117369],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001449515,"about_ca_system_score_gemma":0.002155783,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002275086,"about_ca_topic_score_gemma":0.007102973,"domain_scores_codex":[0.9989625,0.0005556519,0.0000393577,0.000155995,0.00006553729,0.0002209874],"domain_scores_gemma":[0.9987994,0.0003277514,0.000198184,0.0001549029,0.00006235656,0.000457413],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9733196,0.006284484,0.0008222242,0.0002640048,0.0007784889,0.00003446091,0.00007478594,0.0007070398,0.00251696,0.0001255116,0.0008837408,0.01418871],"study_design_scores_gemma":[0.8302129,0.1624038,0.00410538,0.00002755797,0.0006149011,0.00005767494,0.00004770194,0.0005272744,0.0006095553,0.000288564,0.001082888,0.00002177139],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9904673,0.002126405,0.000672289,0.0003897268,0.0003009547,0.002005371,0.001736649,0.0001101391,0.002191202],"genre_scores_gemma":[0.983321,0.001796492,0.001840828,0.0008856202,0.0002334873,0.003675139,0.003440454,0.00007217914,0.004734749],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005841802,"threshold_uncertainty_score":0.01954275,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.100699480469896,"score_gpt":0.4439617932321269,"score_spread":0.343262312762231,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}